mRNA vaccine

mRNA-encoded self-assembling enveloped virus-like particles presenting SARS-CoV-2 spike protein enhance immunity and may provide better protection against viral variants. 

Multiple candidates are in Phase 3 clinical trials for older adults and pregnant women, with some getting close to approval in the United States.

Studies show that a fourth mRNA vaccine dose offers the elderly and other high-risk groups strong protection against hospitalization and death from COVID-19, but experts say benefits for other populations may be more limited.

US adults are now only eligible for the vaccine under certain circumstances.

The vaccine’s effectiveness in children ages 5 to 11 rapidly declined over the course of a month, according to new research that looked at the health outcomes of hundreds of thousands of children in New York during the Omicron surge.

A Hawaii hospital worker who reported the controversial scientist to the Maryland Board of Physicians was subjected to harassment and a retaliatory complaint after Malone made his name and location public.

Specialized immune cells generated in vivo reduce cardiac scar tissue in mice, a new study shows.

All antibodies against SARS-CoV-2 found in breast milk neutralized the virus.

NIH researcher Andaleeb Sajid discusses her study’s finding that ticks were unable to feed on vaccinated guinea pigs, preventing transmission of the pathogen that causes Lyme disease.

A guide to mRNA-based cancer vaccines and where they’re headed next

This year’s winners are Dieter Oesterhelt, Peter Hegemann, Karl Deisseroth, Drew Weissman, Katalin Karikó, and David Baltimore.

Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.  

The milestone marks the first fully-approved COVID-19 vaccine in the United States.

A study looks beyond T and B cell responses to show how the Pfizer COVID-19 vaccine elicits a strong innate immune response.

More than a dozen vaccines for tuberculosis are currently being tested in clinical trials. Some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by viral vectors.